Pegipanermin for COVID-19: real-time analysis

Download Image

Post

c19early.org

Pegipanermin for COVID-19

1 study with 77 patients

Serious outcome risk

Pegipanermin

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Pegipanermin studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−290%

Mortality (1)−290%

Hospitalization (1)−38%

RCTs (1)−290%

Late (1)−290%

00.511.5+

← Pegipanermin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Pegipanermin (XPro1595, INB03) is a biologic immunomodulator that uses dominant-negative TNF technology to selectively inhibit soluble tumor necrosis factor (sTNF) while sparing transmembrane TNF and its receptors.


Nov 18 2021	Tesi et al., NCT04370236	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)
Nov 18 2021	290% higher mortality (p=0.36), 241% higher ICU admission (p=0.15), 62% higher progression (p=0.4), and 38% longer hospitalization (p=0.16). RCT 79 hospitalized COVID-19 patients showing no significant differences with pegipanermin (INB03) treatment.